PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
- 29 July 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Immunology
- Vol. 20 (9), 1231-1243
- https://doi.org/10.1038/s41590-019-0441-y
Abstract
Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1) is crucial for the development of reversal strategies. In anti-PD-1-resistant models, simultaneous anti-PD-1 and vaccine therapy reversed resistance, while PD-1 blockade before antigen priming abolished therapeutic outcomes. This was due to induction of dysfunctional PD-1+CD38hi CD8+ cells by PD-1 blockade in suboptimally primed CD8 cell conditions induced by tumors. This results in erroneous T cell receptor signaling and unresponsiveness to antigenic restimulation. On the other hand, PD-1 blockade of optimally primed CD8 cells prevented the induction of dysfunctional CD8 cells, reversing resistance. Depleting PD-1+CD38hi CD8+ cells enhanced therapeutic outcomes. Furthermore, non-responding patients showed more PD-1+CD38+CD8+ cells in tumor and blood than responders. In conclusion, the status of CD8+ T cell priming is a major contributor to anti-PD-1 therapeutic resistance. PD-1 blockade in unprimed or suboptimally primed CD8 cells induces resistance through the induction of PD-1+CD38hi CD8+ cells that is reversed by optimal priming. PD-1+CD38hi CD8+ cells serve as a predictive and therapeutic biomarker for anti-PD-1 treatment. Sequencing of anti-PD-1 and vaccine is crucial for successful therapy.Keywords
This publication has 55 references indexed in Scilit:
- Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapyJournal for ImmunoTherapy of Cancer, 2013
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2The Journal of Experimental Medicine, 2012
- Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanismsEuropean Journal of Immunology, 2011
- Cell metabolism: An essential link between cell growth and apoptosisBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 2008
- Tailoring T-cell receptor signals by proximal negative feedback mechanismsNature Reviews Immunology, 2008
- Signaling defects in anti‐tumor T cellsImmunological Reviews, 2008
- Interferon γ Is Required for Activation-induced Death of T LymphocytesThe Journal of Experimental Medicine, 2002
- The Impact of Duration versus Extent of TCR Occupancy on T Cell Activation: A Revision of the Kinetic Proofreading ModelImmunity, 2001